- Report
- May 2024
- 132 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- March 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- June 2024
- 200 Pages
Global
From €7547EUR$7,950USD£6,366GBP
- Report
- March 2025
- 198 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- October 2024
- 185 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- August 2024
- 220 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- July 2024
- 130 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- May 2024
- 132 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- May 2024
- 135 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Report
- March 2025
- 196 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 194 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- March 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- October 2024
- 175 Pages
Global
From €4747EUR$5,000USD£4,004GBP
- Report
- May 2024
- 210 Pages
Global
From €4225EUR$4,450USD£3,563GBP
- Report
- December 2024
- 150 Pages
Global
From €3560EUR$3,750USD£3,003GBP
- Report
- October 2024
- 200 Pages
Europe
From €2364EUR$2,490USD£1,994GBP
- Report
- September 2023
- 180 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- January 2024
- 190 Pages
Global
From €4272EUR$4,500USD£3,603GBP

Retinal Vein Occlusion (RVO) is a condition in which the veins in the retina become blocked, leading to vision loss. It is the second most common cause of vision loss in the elderly, and is often caused by hypertension, diabetes, and other vascular diseases. Treatment for RVO includes laser photocoagulation, intravitreal injections, and vitrectomy. Optical treatments such as optical coherence tomography (OCT) and fundus photography are used to diagnose and monitor the condition.
In the RVO market, companies such as Carl Zeiss Meditec, Topcon Corporation, Heidelberg Engineering, Optovue, and Nidek Co. Ltd. are involved in the development and manufacture of optical imaging systems and treatments for RVO. These companies provide a range of products and services, including OCT systems, fundus cameras, laser photocoagulation systems, and intravitreal injections. Show Less Read more